

30th March, 2016

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol : PANACEABIO

Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Fax No.:022-22721919, 3121
BSE Scrip Code: 531349

Re.: Press Release - Panacea Biotec Receives Prestigious Intellectual Property & Science Award "Top 50 Indian Innovators 2015"

Dear Sir,

We wish to inform you that the Company has received Prestigious Intellectual Property & Science Award "Top 50 Indian Innovators 2015" from Thomson Reuters. Thomson Reuters India Innovation Awards honors the most innovative academic institutions and commercial enterprises headquartered in India for their spirit of innovation in R&D as it relates to Indian Patent Publications.


A copy of the Press Release being released in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt.

Further, as required, a pdf version of the letter duly signed by the Compliance Officer is also attached herewith.

Thanking you,


Sincerely yours,

for Panacea Biotec Ltd.



Vinod Goel
Group CFO and Head Legal
& Company Secretary

Encl. As Above.



Panacea Biotec

Innovation in support of life

Press Release:

For Immediate Distribution

Panacea Biotec Receives Prestigious Intellectual Property & Science Award "Top 50 Indian Innovators 2015"

New Delhi, 30th March, 2016: Panacea Biotec, India's 3rd largest biotechnology company received prestigious Thomson Reuters Intellectual Property & Science Award for the year 2015 as **"Top 50 Indian Innovators - 2015"**. The Award was presented to Dr. Rajesh Jain, Jt. Managing Director, Panacea Biotec by Mr. Arvind Pachhapur, South Asia Head- Intellectual Property & Science, Thomson Reuters in New Delhi




Dr. Rajesh Jain, Jt. Managing Director, Panacea Biotec receiving Award from Mr. Arvind Pachhapur, South Asia Head, Intellectual Property & Science, Thomson Reuters in New Delhi

Thomson Reuters India Innovation Awards honors the most innovative academic institutions and commercial enterprises headquartered in India for their spirit of innovation in R&D as it relates to Indian patent publications.



B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: +91-11-4167 9000, 4157 8000, Fax: +91-11-41679070, 41679081, Email: corporate@panaceabiotec.com
CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Website: www.panaceabiotec.com




Panacea Biotec

Innovation in support of life


Thomson Reuters has identified top 50 Indian Innovators across the Indian industry. Thomson Reuters 2015 India Innovation Awards is based on research and analysis done using the Derwent World Patents Index, the world's most trusted and authoritative value-added patent database. Data from 2010-2014 was used for the analysis for the Indian companies. The threshold for inclusion in the Top 50 Indian innovators is at least 25 patents published during the period 2010-2014.

Four metrics were used to assess the level of innovation of candidate companies and identify the top innovators and the awardees.

- Volume of patents (Volume of new inventions published in India during the analysis period)
- Grant success rate (ratio of granted patents to all new inventions published during the analysis period)
- Extent of globalization (number of new invention patents that have foreign (non-India patents) in their patent families)
- Influence of innovation (how often inventions are subsequently cited by other companies, excluding self-citations, leverages data from Derwent Patents Citation Index™ database)



Commenting on the occasion, **Dr. Rajesh Jain**, Jt. Managing Director, Panacea Biotec Limited said, Panacea Biotec will remain committed to its mission **"Innovation in Support of Life"** and continue to provide the Latest and Most Affordable preventive and therapeutic care to patients across the globe. Our highly talented and committed scientific team is doing wonderful job in bringing out most innovative products on regular intervals.



B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: +91-11-4167 9000, 4157 8000, Fax: +91-11-41679070, 41679081, Email: corporate@panaceabiotec.com
CIN: L33117PB1984PLC022350



Panacea Biotec

Innovation in support of life

Notes to Editors:

About Panacea Biotec

Panacea Biotec is one of India's leading research based Pharma-Biotech companies with established research, manufacturing and marketing capabilities. Panacea Biotec is one of the largest vaccine producer in India and has been amongst the top 40 biotechnology companies (Biospectrum – ABLE Survey, July 2014) and the top 60 pharmaceutical companies (AIOCD AWACS – MAT May 2014) in India. The product portfolio of Panacea Biotec includes innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular disease and pediatric immunization vaccines. Panacea Biotec is working on a robust pipeline of high barrier to entry generics and 505(b)(2)s, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro particles, liposomes, gastro-retentive systems. Panacea Biotec has introduced its products in 22 countries across the world including USA and Germany through a combination of strategic collaborations and direct presence in select geographies. Panacea Biotec has research collaborations with leading national and international research organizations and corporations. Panacea Biotec's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has around 2,600 employees including around 125 scientists working across 4 R&D centers of the company.

Intellectual Property

The Panacea Biotec has filed more than 1,500 patent applications worldwide including 230 patent applications in India for different products/ technologies. The Company has been filing foreign applications through PCT route and has filed more than 100 International patent applications through this route. About 450 patent applications have been granted / accepted for grant.


The Company has filed around 700 applications for trademark registration out of which around 460 have been registered. In addition, the Company has also filed 516 International Trademark applications out of which 307 have been granted. The Company had filed 222 applications for registration of Copyrights of which 170 had been registered.

Research & Development:


Research & Development is integral part of the Panacea Biotec's core business strategy. The Company has **four dedicated R&D centers** manned with over 125 scientists working on several key projects in vaccines, pharmaceutical formulations and biopharmaceuticals.

Global Research and Development (GRAND) Center, Navi Mumbai

The GRAND R&D Center has successfully completed development of 5 key projects enabling the Company to file the ANDAs with USFDA. The R&D center has also developed a portfolio of oncological products enabling the Company to shift their production in-house at its Baddi oncology facility.



B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: +91-11-4167 9000, 4157 8000, Fax: +91-11-41679070, 41679081, Email: corporate@panaceabiotec.com
CIN: L33117PB1984PLC022350



Panacea Biotec

Innovation in support of life

Key products already commercialized in India include PacliALL, Bemustin and Docetaxel, and recently launched Cabapan. It is also developing several other critical projects for global markets.

SAMPANN Drug Delivery R&D Center, Lalru, Punjab

Sampann Center focuses on research and development of generics and NDDS technologies such as depot injections, oral modified release, SMEDDS in soft gels, MD tablets, critical dose drugs and bio-therapeutics. Sampann is also supporting in the development of new generation vaccines like Pneumococcal Conjugate Vaccine 10-valent (Nucovac) and Dengue tetravalent vaccine, Easyfour-Pol and Easysix vaccine, Sabin-Inactivated Polio vaccine (S-IPV), Tetanus vaccine, indigenous Pentavalent vaccine, Japanese Encephalitis (JE) vaccine and Measles vaccine.


LAKSH Drug Discovery R&D Center, Mohali, Punjab

Laksh Center focusses on development of New Chemical Entities (NCEs, small molecules) and API research. This R&D center has successfully delivered three Pre-Clinical Candidates (PCCs), two of which are currently under investigation for IND (Investigational New Drug) filing at different stages of phase I studies in India. In diabetes, efforts are on to develop a formulation for once a week dosing.

OneStream Research Center, New Delhi

OneStream Center carry out extensive research in vaccines and biologicals using genetic engineering, molecular biology, genomics tools, animal cell culture, fermentation, purification, formulation, serology and analytical testing techniques. The center has well-established P3 facility to handle pathogenic viruses like H1N1, seasonal flu and JE virus. The center has also indigenously developed and licensed Pandylflu against H1N1 virus. OneStream Centre is engaged in research of new generation vaccines like Pneumococcal Conjugate Vaccine 10-valent (Nucovac), Dengue tetravalent vaccine, Sabin-Inactivated Polio vaccine (s-IPV), Japanese encephalitis (JE) vaccine, etc.

For more information, please contact –


Mr. P. D. Karan

Vice President - Business Diversification & Corporate Communication

B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,

Mathura Road, New Delhi – 110044, INDIA

Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)

Fax + 91 11 41578002

Mobile: + 91 9312693040, + 91 9810500539

Email: pdkaran@panaceabiotec.com

Web: www.panaceabiotec.com



B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi – 110 044, India
Ph.: +91-11-4167 9000, 4157 8000, Fax: +91-11-41679070, 41679081, Email: corporate@panaceabiotec.com
CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru – 140 501, Punjab, India. Website: www.panaceabiotec.com